NKMAX said on Thursday that it has received FDA approval for its natural killer (NK) cell therapy SNK01 to treat Parkinson's disease under the Expanded Access Program (EAP).This makes NKMAX the first Korean biotech company to administer NK cell therapy to Parkinson's patients with compassionate use
“Nations that permitted DCT (Decentralized Clinical Trials) practice will continue to speed up their trial completion rate, delivering life-saving therapies to patients quicker. Korea (and other nations with DCT hesitancy) should seriously consider these technologies, or they risk falling behind the
The Yonsei University Health System (YUHS) will become Korea's first hospital to operate a heavy ion therapy device, regarded by physicians as a dream treatment for cancer patients when it receives approval from the Ministry of Food and Drug Safety in the first half of 2023. Within Yonsei Cancer Cen
Not long after establishing 3billion, I had an opportunity to participate in a rare patient advocacy summit held in Irvine, California, in September 2017, organized by Global Genes, the world’s largest rare disease group. Although the event was mainly for rare disease patients and their families, gl
While Medytox and Daewoong have been embroiled in court matters over the source of a botulinum toxin (BTX) strain, from the consumer’s perspective, a growing issue of concern is resistance to BTX.It is no secret that Korea has a large BTX market driven by its high emphasis on beauty standards. In No
President Yoon Suk-yeol ordered government officials to expand and reorganize the 24-hour pediatric emergency care system and promised that the government would spare no support in strengthening the pediatric medical system so that children can grow up healthy.Attending the policy discussion held at
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has vowed to focus on building an ecosystem to create new blockbuster drugs and enhance industrial competitiveness this year.At its general meeting on Tuesday, the association finalized its business plan, composed of 16 core t
Twelve study papers written by Korean research institutions were included in the 500 excellent papers in 2021 selected by the international academic journal Nature. Seoul National University (SNU) ranked 59th, the highest among Korean research institutions.On Tuesday, the Korea Biotech Policy Resear
Researchers at Seoul National University (SNU) College of Medicine found that those who consistently consumed foods made from soybeans such as tofu and soybean paste have a significantly lower risk of developing stomach cancer.A joint research team led by Professors Shin Woo-kyoung and Kang Dae-hee
Medtronic, a U.S. medical device company, is reportedly seeking to acquire EOflow, a Korean company specializing in wearable insulin pumps.According to Aju Business Daily, EOFlow is said to have selected Credit Suisse as the organizer of the sale."Rumor is circulating that Medtronic has entered the
As the survival rate of childhood cancer increases, various methods are being sought to improve the quality of life after treatment.Dental health is one factor that greatly affects the quality of life, and pediatric cancer patients who have undergone hematopoietic stem cell transplantation, which tr
The B cell, cited as the core of immune response, can accelerate the progression of Alzheimer’s disease, a recent study showed.Professor Park Jong-chan of the Department of Biophysics at Sung Kyun Kwan University released the result of his “Study on B lymphocyte profiling and its association with mi
Severance Cardiovascular Hospital recently announced that they recorded a total of 25,000 arrhythmia treatment results since 1986 -- the highest number among Korean hospitals.Among the 25,000 treatments, more than 19,500 were radiofrequency catheter ablations and around 5,900 were implantable electr
MSD’s attempt to expand the indication of its Covid-19 oral treatment Lagevrio (molnupravir) to post-exposure preventive treatment has ended in failure.MSD said Tuesday (local time) that it failed to prove the efficacy of Lagebrio in post-exposure preventive treatment due to the MOVe-AHEAD study, a
Alteogen said on Wednesday that it completed patient recruitment for the global phase 3 clinical trials of ALT-L9, its Eylea (ingredient: aflibercerpt) biosimilar being clinically developed by its subsidiary Altos Biologics.Eylea treats diabetic macular edema (DME) and wet age-related macular degene
The government has decided to lift the mandatory Covid-19 polymerase chain reaction (PCR) test for entrants from China from March 1.Quarantine officials also stressed that it will drop the measure that made flights from China only arrive at Incheon Airport in March as well."The domestic Covid-19 sit
Super-activated natural killer (SNK) therapy, a Korean NK-cell therapy, is expected to be used in pediatric sarcoma patients at MD Anderson Cancer Center, the developer of the therapy said. NKGen Biotech, a U.S. subsidiary of the Korean biotech firm NKMAX, said on Monday that MD Anderson Cancer Cent
"To prevent Covid-19 infection in the hospital, visits to the monitoring room will be banned from May 29, 2020."That was a notice posted at a clinical trial center of a university hospital during the Covid-19 pandemic. As such, there have been a series of cases in which patients cannot visit clinica
Korea Biomedical Review is publishing a series of articles to analyze the top 10 Korean pharmaceutical and biopharma companies with the largest market capitalizations listed on the main bourse, Kospi, and the tech-heavy Kosdaq. The series aims to reflect key industrial issues and the flow of the cap
Recently designated as an innovative pharmaceutical company by the Ministry of Health and Welfare, Bridge Biotherapeutics has already joined forces with Pinotbio to develop ADC cancer drug candidates, displaying its tenacity to pursue novel drugs.Bridge Biotherapeutics' Business Development Director